Precision BioSciences Inc. (DTIL) reported first‑quarter 2026 revenue of $10.8 million, a dramatic increase from the less than $0.1 million recorded in Q1 2025. The jump was largely driven by milestone payments from licensing agreements and early clinical program revenue, and it surpassed analysts’ consensus estimate of $4.05 million by $6.75 million.
The company posted a net loss of $18.4 million, or $0.75 per share, compared with a $20.6 million loss in Q1 2025. Adjusted for non‑recurring items, the loss narrowed to $0.34 per share. Earnings per share of $‑0.75 missed the consensus estimate of $‑0.27 by $0.48 per share, reflecting continued investment in clinical development despite a modest improvement in operating efficiency.
Milestone revenue from collaborations and early clinical program revenue were the primary drivers of the revenue growth. Precision’s ARCUS‑based gene‑editing programs in hepatitis B (PBGENE‑HBV) and Duchenne muscular dystrophy (PBGENE‑DMD) progressed, with PBGENE‑DMD receiving FDA Fast Track designation and the company activating its first clinical site for the FUNCTION‑DMD trial.
Cash and cash equivalents stood at $125.8 million as of March 31 2026, giving the company a runway that management expects to extend through 2028, assuming continued access to its at‑the‑market equity facility.
CEO Michael Amoroso highlighted progress in the company’s flagship programs, noting that PBGENE‑HBV had entered new cohorts in the ELIMINATE‑B trial and that PBGENE‑DMD had achieved IND approval and begun patient enrollment in the FUNCTION‑DMD trial. He emphasized disciplined execution in 2026 as the company gathers additional clinical data and expands site and patient enrollment.
Investors responded positively to the results, citing the strong revenue beat and the company’s progress in key clinical programs as encouraging signs of future growth potential.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.